Literature DB >> 32175894

Prevalence and clinical impact of sarcopenia in osteoporotic hip fracture: Single center retrospective cohort study.

Won Chul Shin1, Jae Hoon Jang2, Han Eol Seo2, Kuen Tak Suh1, Nam Hoon Moon2.   

Abstract

OBJECTIVE: The study aimed to identify the prevalence of sarcopenia in patients with osteoporotic hip fractures, investigate the anthropometric differences between sarcopenic and non-sarcopenic patients, and evaluate and compare the surgical outcomes between the two groups.
METHODS: The study included 135 patients (35 men and 100 women; mean age: 74.1 years (range; 25-96)) who received surgical treatment for hip fracture between March 2014 and October 2016 and underwent whole-body dual-energy X-ray absorptiometry (DEXA). The skeletal muscle mass index (SMI) for diagnosis of sarcopenia was measured using whole-body DEXA. The following data were collected to compare the preoperative details of the sarcopenic and non-sarcopenic groups: SMI, age, sex, type of fracture, type of operation, BMI, obesity, American society of Anesthesiologists (ASA) class, pre-injury mobility score, BMD, and follow-up period. We compared clinical outcomes, including Harris Hip Score (HSS) and the walking ability at the last follow-up visit and radiologic outcomes, including non-union and the time to union.
RESULTS: The average HHS and Parker's mobility score at the last follow-up were 81.7 and 6.9 in the sarcopenic group, and 77.6 and 6.3 in the non-sarcopenic group, respectively (p=0.149 and 0.122). Non-union was identified 0 (0%) in sarcopenic group and 4 (10%) in non-sarcopenic group (p=0.288). The mean union timer of the patients in the sarcopenia group was 4.0 months and that of patients in the non-sarcopenic group was 4.4 months (p=0.210). Multiple regression analysis did not show any significant association between sarcopenia and postoperative surgical outcomes, including HHS, mobility score at the last follow up, non-union, and time to union.
CONCLUSION: Although the present study showed that the prevalence of sarcopenia in hip fracture patients was 45.9% (62/135), there was no clinical association between sarcopenia and postoperative. Based on these results, the clinical impact of sarcopenia may be confined to increased risk of hip fracture occurrence and surgical outcomes of hip fracture may not be affected by sarcopenia. LEVEL OF EVIDENCE: Level III, Therapeutic Study.

Entities:  

Year:  2020        PMID: 32175894      PMCID: PMC7243698          DOI: 10.5152/j.aott.2020.01.476

Source DB:  PubMed          Journal:  Acta Orthop Traumatol Turc        ISSN: 1017-995X            Impact factor:   1.511


  23 in total

1.  Sarcopenia is more prevalent in men than in women after hip fracture: a cross-sectional study of 591 inpatients.

Authors:  Marco Di Monaco; Carlotta Castiglioni; Fulvia Vallero; Roberto Di Monaco; Rosa Tappero
Journal:  Arch Gerontol Geriatr       Date:  2012-05-28       Impact factor: 3.250

2.  Skeletal muscle: an endocrine organ.

Authors:  Alessandra Pratesi; Francesca Tarantini; Mauro Di Bari
Journal:  Clin Cases Miner Bone Metab       Date:  2013-01

3.  High prevalence of sarcopenia and reduced leg muscle mass in Japanese patients immediately after a hip fracture.

Authors:  Tetsuro Hida; Naoki Ishiguro; Hiroshi Shimokata; Yoshihito Sakai; Yasumoto Matsui; Marie Takemura; Yasuto Terabe; Atsushi Harada
Journal:  Geriatr Gerontol Int       Date:  2012-07-23       Impact factor: 2.730

4.  Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial.

Authors:  R Sih; J E Morley; F E Kaiser; H M Perry; P Patrick; C Ross
Journal:  J Clin Endocrinol Metab       Date:  1997-06       Impact factor: 5.958

5.  Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women.

Authors:  Michele Iannuzzi-Sucich; Karen M Prestwood; Anne M Kenny
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2002-12       Impact factor: 6.053

6.  Sarcopenia as a risk factor for falls in elderly individuals: results from the ilSIRENTE study.

Authors:  Francesco Landi; Rosa Liperoti; Andrea Russo; Silvia Giovannini; Matteo Tosato; Ettore Capoluongo; Roberto Bernabei; Graziano Onder
Journal:  Clin Nutr       Date:  2012-03-11       Impact factor: 7.324

7.  Recurrent and injurious falls in the year following hip fracture: a prospective study of incidence and risk factors from the Sarcopenia and Hip Fracture study.

Authors:  Bradley D Lloyd; Dominique A Williamson; Nalin A Singh; Ross D Hansen; Terrence H Diamond; Terence P Finnegan; Barry J Allen; Jodie N Grady; Theodora M Stavrinos; Emma U R Smith; Ashish D Diwan; Maria A Fiatarone Singh
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-03-05       Impact factor: 6.053

8.  Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study.

Authors:  J E Morley; H M Perry; F E Kaiser; D Kraenzle; J Jensen; K Houston; M Mattammal; H M Perry
Journal:  J Am Geriatr Soc       Date:  1993-02       Impact factor: 5.562

Review 9.  Bone and skeletal muscle: neighbors with close ties.

Authors:  Douglas J DiGirolamo; Douglas P Kiel; Karyn A Esser
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

10.  Trend in hip fracture incidence and mortality in Korea: a prospective cohort study from 2002 to 2011.

Authors:  Yong-Chan Ha; Yong-Geun Park; Kwang Woo Nam; Sang-Rim Kim
Journal:  J Korean Med Sci       Date:  2015-03-19       Impact factor: 2.153

View more
  2 in total

1.  Potential association of bone mineral density loss with cognitive impairment and central and peripheral amyloid-β changes: a cross-sectional study.

Authors:  Peng Zhang; Yi Zhou; Gang Chen; Jun Li; Bangjun Wang; Xinyan Lu
Journal:  BMC Musculoskelet Disord       Date:  2022-06-30       Impact factor: 2.562

Review 2.  Undernutrition, Sarcopenia, and Frailty in Fragility Hip Fracture: Advanced Strategies for Improving Clinical Outcomes.

Authors:  Tatsuro Inoue; Keisuke Maeda; Ayano Nagano; Akio Shimizu; Junko Ueshima; Kenta Murotani; Keisuke Sato; Atsuhiro Tsubaki
Journal:  Nutrients       Date:  2020-12-04       Impact factor: 5.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.